|
1
|
Kikkawa F, Nawa A, Ino K, Shibata K,
Kajiyama H and Nomura S: Advances in treatment of epithelial
ovarian cancer. Nagoya J Med Sci. 68:19–26. 2006.PubMed/NCBI
|
|
2
|
Brun JL, Feyler A, Chêne G, Saurel J, Brun
G and Hocké C: Long-term results and prognostic factors in patients
with epithelial ovarian cancer. Gynecol Oncol. 78:21–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K
and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis
compared to other epithelial cell types? A study of 1411 clear cell
ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryu SY, Park SI, Nam BH, Kim I, Yoo CW,
Nam JH, Lee KH, Cho CH, Kim JH, Park SY, et al: Prognostic
significance of histological grade in clear-cell carcinoma of the
ovary: A retrospective study of Korean gynecologic oncology group.
Ann Oncol. 20:1032–1036. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gynecology JSoOa: Annual patient report.
Acta Obstet Gynaecologia Japonica. 68:1117–1160. 2016.
|
|
6
|
Jenison EL, Montag AG, Griffiths CT, Welch
WR, Lavin PT, Greer J and Knapp RC: Clear cell adenocarcinoma of
the ovary: A clinical analysis and comparison with serous
carcinoma. Gynecol Oncol. 32:65–71. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kennedy AW, Biscotti CV, Hart WR and
Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol.
32:342–349. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Satoh T, Oki A, Uno K, Sakurai M, Ochi H,
Okada S, Minami R, Matsumoto K, Tanaka YO, Tsunoda H, et al: High
incidence of silent venous thromboembolism before treatment in
ovarian cancer. Br J Cancer. 97:1053–1057. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizuno M, Kikkawa F, Shibata K, Kajiyama
H, Ino K, Kawai M, Nagasaka T and Nomura S: Long-term follow-up and
prognostic factor analysis in clear cell adenocarcinoma of the
ovary. J Surg Oncol. 94:138–143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan GR, Zou FY, Dang BL, Zhang Y, Yu G,
Liu X and He QY: Genistein-induced mitotic arrest of gastric cancer
cells by downregulating KIF20A, a proteomics study. Proteomics.
12:2391–2399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Liu J, Peng X, Zhu CC, Han J, Luo
J and Rui R: KIF20A regulates porcine oocyte maturation and early
embryo development. PLoS One. 9:e1028982014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Echard A, Jollivet F, Martinez O, Lacapere
JJ, Rousselet A, Janoueix-Lerosey I and Goud B: Interaction of a
Golgi-associated kinesin-like protein with Rab6. Science.
279:580–585. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai F, Fernald AA, Zhao N and Le Beau MM:
cDNA cloning, expression pattern, genomic structure and chromosomal
location of RAB6KIFL, a human kinesin-like gene. Gene. 248:117–125.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stangel D, Erkan M, Buchholz M, Gress T,
Michalski C, Raulefs S, Friess H and Kleeff J: Kif20a inhibition
reduces migration and invasion of pancreatic cancer cells. J Surg
Res. 197:91–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ho JR, Chapeaublanc E, Kirkwood L, Nicolle
R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F and Goud
B: Deregulation of Rab and Rab effector genes in bladder cancer.
PLoS One. 7:e394692012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imai K, Hirata S, Irie A, Senju S, Ikuta
Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, et al:
Identification of HLA-A2-restricted CTL epitopes of a novel
tumour-associated antigen, KIF20A, overexpressed in pancreatic
cancer. Br J Cancer. 104:300–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taniuchi K, Furihata M and Saibara T:
KIF20A-mediated RNA granule transport system promotes the
invasiveness of pancreatic cancer cells. Neoplasia. 16:1082–1093.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gasnereau I, Boissan M, Margall-Ducos G,
Couchy G, Wendum D, Bourgain-Guglielmetti F, Desdouets C, Lacombe
ML, Zucman-Rossi J and Sobczak-Thépot J: KIF20A mRNA and its
product MKlp2 are increased during hepatocyte proliferation and
hepatocarcinogenesis. Am J Pathol. 180:131–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Exertier P, Javerzat S, Wang B, Franco M,
Herbert J, Platonova N, Winandy M, Pujol N, Nivelles O, Ormenese S,
et al: Impaired angiogenesis and tumor development by inhibition of
the mitotic kinesin Eg5. Oncotarget. 4:2302–2316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khongkow P, Gomes AR, Gong C, Man EP,
Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US and
Lam EW: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zou JX, Duan Z, Wang J, Sokolov A, Xu J,
Chen CZ, Li JJ and Chen HW: Kinesin family deregulation coordinated
by bromodomain protein ANCCA and histone methyltransferase MLL for
breast cancer cell growth, survival, and tamoxifen resistance. Mol
Cancer Res. 12:539–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang W, He W, Shi Y, Gu H, Li M, Liu Z,
Feng Y, Zheng N, Xie C and Zhang Y: High expression of KIF20A is
associated with poor overall survival and tumor progression in
early-stage cervical squamous cell carcinoma. PLoS One.
11:e01674492016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu SL, Lin HX, Qiu F, Zhang WJ, Niu CH,
Wen W, Sun XQ, Ye LP, Wu XQ, Lin CY, et al: Overexpression of
Kinesin family member 20A correlates with disease progression and
poor prognosis in human nasopharyngeal cancer: A retrospective
analysis of 105 patients. PLoS One. 12:e01692802017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi C, Huang D, Lu N, Chen D, Zhang M, Yan
Y, Deng L, Lu Q, Lu H and Luo S: Aberrantly activated Gli2-KIF20A
axis is crucial for growth of hepatocellular carcinoma and predicts
poor prognosis. Oncotarget. 7:26206–26219. 2016.PubMed/NCBI
|
|
27
|
Hosono S, Kajiyama H, Terauchi M, Shibata
K, Ino K, Nawa A and Kikkawa F: Expression of Twist increases the
risk for recurrence and for poor survival in epithelial ovarian
carcinoma patients. Br J Cancer. 96:314–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen VW, Ruiz B, Killeen JL, Cote TR, Wu
XC and Correa CN: Pathology and classification of ovarian tumors.
Cancer. 97:2631–2642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sakata J, Kajiyama H, Suzuki S, Utsumi F,
Niimi K, Sekiya R, Shibata K, Senga T and Kikkawa F: Impact of
positive ZEB1 expression in patients with epithelial ovarian
carcinoma as an oncologic outcome-predicting indicator. Oncol Lett.
14:4287–4293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duan J, Huang W and Shi H: Positive
expression of KIF20A indicates poor prognosis of glioma patients.
Onco Targets Ther. 9:6741–6749. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kajiyama H, Shibata K, Mizuno M, Yamamoto
E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T and
Kikkawa F: Postrecurrent oncologic outcome of patients with ovarian
clear cell carcinoma. Int J Gynecol Cancer. 22:801–806. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tcherniuk S, Skoufias DA, Labriere C, Rath
O, Gueritte F, Guillou C and Kozielski F: Relocation of Aurora B
and survivin from centromeres to the central spindle impaired by a
kinesin-specific MKLP-2 inhibitor. Angew Chem Int Ed Engl.
49:8228–8231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kajiyama H, Shibata K, Terauchi M, Ino K,
Nawa A and Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the
enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int
J Cancer. 122:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Terauchi M, Kajiyama H, Yamashita M, Kato
M, Tsukamoto H, Umezu T, Hosono S, Yamamoto E, Shibata K, Ino K, et
al: Possible involvement of TWIST in enhanced peritoneal metastasis
of epithelial ovarian carcinoma. Clin Exp Metastasis. 24:329–339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shimada M, Kigawa J, Ohishi Y, Yasuda M,
Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T and Kaku T:
Clinicopathological characteristics of mucinous adenocarcinoma of
the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Suzuki N, Hazama S, Ueno T, Matsui H,
Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K and Oka M: A
phase I clinical trial of vaccination with KIF20A-derived peptide
in combination with gemcitabine for patients with advanced
pancreatic cancer. J Immunother. 37:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asahara S, Takeda K, Yamao K, Maguchi H
and Yamaue H: Phase I/II clinical trial using HLA-A24-restricted
peptide vaccine derived from KIF20A for patients with advanced
pancreatic cancer. J Transl Med. 11:2912013. View Article : Google Scholar : PubMed/NCBI
|
